文献速递乳腺癌放疗姑息放疗与转移瘤

症状性局部区域晚期乳腺癌患者接受姑息性放射治疗后的结局

Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2024-11-15

单机构多院区回顾性分析2016至2023年164例症状性局部区域晚期乳腺癌患者,中位随访4.97个月,中位年龄57岁,86%有远处转移。中位GTV生物有效剂量69Gy,1年总生存率37%、局部区域控制率63%,81%患者在放疗后3个月内症状改善,且改善几率随BEDGTV每增加1Gy而升高(OR 1.029,P=.003)。

要点

  • 症状改善几率随GTV生物有效剂量每增加1Gy而升高(OR 1.029,P=.003)。
  • 1年总生存率37%、局部区域控制率63%,生存仍较差。
  • 急性毒性仅与分次数和BEDGTV相关(均P<.001)。

核心结论

  • 在这组较大的症状性局部区域晚期乳腺癌患者中,姑息性放疗能有效缓解局部区域症状且毒性可接受,症状改善的可能性与放射剂量相关;患者生存仍较差,凸显了在最大化生活质量的同时最小化总体症状负担的姑息治疗策略的重要性。

研究设计与样本

  • 单机构、多院区回顾性综述,纳入2016年至2023年间因乳腺、胸壁和/或区域淋巴结引流区症状性疾病接受姑息性放疗的症状性局部区域晚期乳腺癌患者,共164例,中位年龄57岁,中位随访4.97个月。

主要发现

  • 共164例患者,中位年龄57岁,中位随访4.97个月,86%有远处转移。
  • 最常见首发症状为疼痛(87%),其次为溃疡性或蕈样病变(76%)和分泌物(45%)。
  • 至大体肿瘤体积的中位累积生物有效剂量(BEDGTV)为69Gy。
  • 1年总生存率和局部区域控制率分别为37%和63%。
  • 81%患者在放疗后3个月内症状改善,改善几率随BEDGTV每增加1Gy而升高(OR 1.029,P=.003);急性毒性与分次数和BEDGTV相关(均P<.001),与同步全身治疗或再程放疗无关(均P>.05);疼痛评分轨迹在放疗后第一年内出现持续显著变化;接受1次、2至10次和>10次分次的患者间,以及BEDGTV≤70Gy与>70Gy组间,总生存和局部区域控制无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Symptomatic locoregionally advanced breast cancer (SLABC) can cause troublesome pain or wound complications that negatively impact quality of life. Although palliative radiation therapy (RT) can minimize tumor-related symptoms, how best to tailor RT to achieve the most meaningful and durable response is not well defined. METHODS AND MATERIALS: This is a single institution, multi-site retrospective review of patients with SLABC treated between 2016 and 2023 with palliative RT to symptomatic disease in the breast, chest wall, and/or regional lymph node basins. Overall survival (OS), locoregional control (LC), clinical and radiographic treatment response, overall pain scores, and treatment-related toxicities were analyzed. RESULTS: A total of 164 patients with a median age of 57 years were analyzed with a median follow-up time of 4.97 months. In total, 86% had distant metastases. The most common presenting symptom was pain (87%), followed by ulcerating or fungating lesion (76%) and discharge (45%). The median cumulative biologically effective dose to the gross tumor volume (BEDGTV) was 69 Gy. The 1-year OS and LC rates were 37% and 63%, respectively. Eighty-one percent experienced improvement in symptoms within 3 months after RT, the odds of which increased per Gy BEDGTV (odds ratio, 1.029; P = .003). Acute toxicities were associated with number of fractions and BEDGTV (both P < .001), but not with concurrent systemic therapy or reirradiation (both P > .05). Trends in pain scores showed a significant change in pain trajectory that was sustained during the first year after RT. OS and LC were not different among patients who received 1 versus 2 to 10 versus >10 fractions, and between ≤70 and >70 Gy BEDGTV. CONCLUSIONS: In this large series of patients with SLABC, palliative RT was effective at relieving locoregional symptoms with acceptable toxicity, with the likelihood of symptom improvement associated with radiation dose. Survival of these patients remains poor, highlighting the importance of palliative care strategies that minimize overall symptom burden while maximizing quality of life.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Jacomina LE, Swanson DM, Mitchell MP, et al. Outcomes After Palliative Radiation Therapy in Patients With Symptomatic Locoregionally Advanced Breast Cancer. Int J Radiat Oncol Biol Phys. 2024. PMID: 39549757. doi:10.1016/j.ijrobp.2024.11.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。